BGNE - BeiGene Ltd Stock Price, Fair Value and News

133.38USD+1.52 (+1.15%)Delayed as of 18 Apr 2024, 12:58 pm ET

Market Summary

USD133.38+1.52

Delayedas of 18 Apr 2024, 12:58 pm

1.15%

BGNE Alerts

1 major insider sales recently.

BGNE Stock Price

View Fullscreen

BGNE RSI Chart

BGNE Valuation

Market Cap

179.3B

Price/Earnings (Trailing)

-203.32

Price/Sales (Trailing)

72.91

EV/EBITDA

-267.25

Price/Free Cashflow

-104.26

BGNE Price/Sales (Trailing)

BGNE Profitability

EBT Margin

-33.59%

Return on Equity

-24.93%

Return on Assets

-15.19%

Free Cashflow Yield

-0.96%

BGNE Fundamentals

BGNE Revenue

Revenue (TTM)

2.5B

Rev. Growth (Yr)

66.91%

Rev. Growth (Qtr)

-18.8%

BGNE Earnings

Earnings (TTM)

-881.7M

Earnings Growth (Yr)

17.47%

Earnings Growth (Qtr)

-270.63%

Breaking Down BGNE Revenue

52 Week Range

131.40266.67

(Low)(High)

Last 7 days

-11.9%

Last 30 days

-21.7%

Last 90 days

-20.2%

Trailing 12 Months

-50.6%

How does BGNE drawdown profile look like?

BGNE Financial Health

Current Ratio

2.32

Debt/Equity

0.4

Debt/Cashflow

-0.83

BGNE Investor Care

Shares Dilution (1Y)

0.25%

Diluted EPS (TTM)

-0.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.6B	1.8B	2.2B	2.5B
2022	877.0M	1.1B	1.2B	1.4B
2021	862.7M	947.0M	1.1B	1.2B
2020	402.4M	224.7M	265.7M	308.9M
2019	243.5M	434.1M	430.0M	428.2M
2018	281.1M	323.7M	157.7M	198.2M
2017	0	0	180.6M	238.4M
2016	8.1M	7.1M	64.9M	122.8M
2015	12.0M	10.9M	9.9M	8.8M
2014	0	0	0	13.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of BeiGene Ltd

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	oyler john	sold	-1,773,090	146	-12,084	chief executive officer
Apr 10, 2024	oyler john	sold	-3,977,860	148	-26,716	chief executive officer
Apr 09, 2024	oyler john	sold	-1,724,080	153	-11,200	chief executive officer
Mar 13, 2024	oyler john	sold	-2,189,650	177	-12,332	chief executive officer
Mar 12, 2024	oyler john	sold	-6,178,370	164	-37,668	chief executive officer
Mar 11, 2024	glazer donald w.	gifted	-	-	-82,020	-
Feb 29, 2024	wang julia aijun	sold	-66,330	167	-397	chief financial officer
Nov 30, 2023	wang xiaodong	sold	-	-	-172,372	-
Nov 30, 2023	wang xiaodong	gifted	-	-	-71,890	-
Nov 14, 2023	baker bros. advisors lp	sold	-198,550,000	180	-1,100,000	-

Which funds bought or sold BGNE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	Harbour Capital Advisors, LLC	sold off	-100	-461,739	-	-%
Apr 15, 2024	MATTHEWS INTERNATIONAL CAPITAL MANAGEMENT LLC	sold off	-100	-3,769,880	-	-%
Apr 12, 2024	AdvisorNet Financial, Inc	new	-	313	313	-%
Apr 11, 2024	SANDERS MORRIS HARRIS LLC	unchanged	-	-37,439	422,253	0.08%
Apr 10, 2024	Bruce G. Allen Investments, LLC	sold off	-100	-1,443	-	-%
Apr 09, 2024	MATHER GROUP, LLC.	new	-	721	721	-%
Apr 05, 2024	CWM, LLC	added	53.85	4,000	16,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	142	4,378	7,194	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-43.85	-57,536	74,129	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	450	63,307,900	77,316,400	0.01%

Are Funds Buying or Selling BGNE?

Are funds buying BGNE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BGNE

No. of Funds

BGNE Alerts

1 major insider sales recently.

Unveiling BeiGene Ltd's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	capital international investors	7.6%	103,421,157	SC 13G/A
Feb 05, 2024	oyler john	5.2%	71,464,808	SC 13G/A
Nov 14, 2023	baker bros. advisors lp	10.2%	138,222,377	SC 13D/A
May 05, 2023	baker bros. advisors lp	11.2%	152,522,377	SC 13D/A
Feb 14, 2023	hhlr advisors, ltd.	10.9%	147,043,058	SC 13D/A
Feb 13, 2023	capital international investors	8.2%	110,215,170	SC 13G/A
Feb 10, 2023	invesco ltd.	2.6%	35,678,240	SC 13G/A
Feb 10, 2023	oyler john	5.1%	70,026,397	SC 13G/A
Aug 16, 2022	hhlr advisors, ltd.	10.9%	147,035,258	SC 13D/A
Feb 14, 2022	oyler john	5.1%	69,558,605	SC 13G/A

Recent SEC filings of BeiGene Ltd

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	PRE 14A	PRE 14A
Apr 11, 2024	4	Insider Trading
Apr 09, 2024	144	Notice of Insider Sale Intent
Mar 26, 2024	144	Notice of Insider Sale Intent
Mar 26, 2024	3	Insider Trading
Mar 20, 2024	8-K	Current Report
Mar 15, 2024	8-K	Current Report
Mar 14, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 12, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to BeiGene Ltd)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.96	14.6	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.72	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.8	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.22	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

BeiGene Ltd News

Latest updates

BeiGene Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-18.8%	634,409,000	781,308,000	595,261,000	447,801,000	380,095,000	387,628,000	341,572,000	306,626,000	213,979,000	206,440,000	149,992,000	605,872,000	100,100,000	91,080,000	65,635,000	52,059,000	56,892,000	50,141,000	243,346,000	77,833,000	58,670,000
Costs and Expenses	-30.3%	638,284,000	915,276,000	913,976,000	819,059,000	562,242,000	825,985,000	780,971,000	749,913,000	620,812,000	668,765,000	624,830,000	535,705,000	585,012,000	531,217,000	424,512,000	425,815,000	444,929,000	362,407,000	329,179,000	251,588,000	339,478,000
S&GA Expenses	14.3%	416,547,000	364,421,000	395,034,000	328,499,000	328,984,000	322,892,000	331,403,000	294,573,000	306,501,000	269,227,000	232,289,000	182,106,000	208,209,000	160,837,000	124,049,000	107,081,000	143,354,000	105,002,000	82,248,000	57,645,000	72,490,000
R&D Expenses	9.0%	493,987,000	453,259,000	422,764,000	408,584,000	446,023,000	426,363,000	378,207,000	389,915,000	430,485,000	351,937,000	356,091,000	320,726,000	355,537,000	349,070,000	285,968,000	304,302,000	283,259,000	236,968,000	228,760,000	178,351,000	257,464,000
EBITDA Margin	20.4%	-0.27	-0.34	-0.85	-1.12	-1.30	-1.62	-1.80	-2.13	-1.20	-1.23	-1.39	-1.35	-	-	-	-	-	-	-	-	-
Interest Expenses	-38.9%	16,274,000	26,649,000	15,070,000	16,016,000	18,219,000	12,759,000	11,431,000	10,071,000	-4,482,000	-2,230,000	-4,866,000	-4,179,000	-5,186,000	-614,000	1,108,000	6,690,000	-438,000	2,206,000	2,886,000	4,477,000	5,950,000
Income Taxes	20.5%	16,781,000	13,925,000	13,674,000	11,492,000	14,370,000	6,318,000	8,141,000	13,949,000	11,463,000	5,036,000	-230,000	-4,630,000	18,741,000	-8,423,000	-1,475,000	1,554,000	7,561,000	-3,217,000	2,129,000	519,000	-8,544,000
Earnings Before Taxes	-252.9%	-350,772,000	229,338,000	-367,463,000	-336,939,000	-430,965,000	-551,238,000	-557,585,000	-421,249,000	-586,804,000	-433,078,000	-480,571,000	61,865,000	-481,976,000	-435,040,000	-337,793,000	-363,385,000	-380,334,000	-311,877,000	-83,825,000	-167,550,000	-275,254,000
EBT Margin	18.3%	-0.34	-0.41	-0.93	-1.21	-1.38	-1.69	-1.87	-2.19	-1.22	-1.26	-1.41	-1.38	-	-	-	-	-	-	-	-	-
Net Income	-270.6%	-367,553,000	215,413,000	-381,137,000	-348,431,000	-445,335,000	-557,556,000	-565,726,000	-435,198,000	-590,678,000	-438,114,000	-484,604,000	55,580,000	-472,745,000	-425,224,000	-336,318,000	-364,939,000	-388,061,000	-307,357,000	-85,570,000	-167,640,000	-268,255,000
Net Income Margin	17.6%	-0.36	-0.44	-0.96	-1.23	-1.42	-1.72	-1.90	-2.22	-1.24	-1.26	-1.40	-1.37	-	-	-	-	-	-	-	-	-
Free Cashflow	-60.4%	-378,597,000	-236,032,000	-415,358,000	-689,362,000	-439,549,000	-670,561,000	-430,249,000	-281,694,000	-622,818,000	-562,756,000	-458,797,000	82,706,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	5.1%	5,805	5,525	5,729	5,957	6,379	6,726	7,378	8,021	8,536	5,286	5,524	5,821	5,601	5,566	3,903	4,067	1,612	1,881	2,150	2,172	2,250
Current Assets	3.7%	4,203	4,054	4,401	4,704	5,207	5,749	6,346	6,948	7,614	4,433	4,799	5,141	4,961	4,966	3,392	3,595	1,173	1,436	1,756	1,797	1,944
Cash Equivalents	3.4%	3,172	3,067	3,410	3,539	3,870	4,197	4,531	4,347	4,376	1,383	1,776	1,902	1,390	1,464	1,345	1,957	621	857	919	764	741
Inventory	31.3%	416	317	321	297	282	291	262	246	243	151	118	73.00	89.00	36.00	33.00	29.00	29.00	38.00	49.00	13.00	16.00
Net PPE	12.4%	1,324	1,178	1,032	925	846	682	633	625	588	451	395	374	358	291	258	240	242	226	213	198	157
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00
Liabilities	28.7%	2,268	1,762	1,930	1,799	1,996	2,071	2,076	2,136	2,403	1,929	1,917	1,817	1,732	1,270	1,357	1,240	634	587	579	550	496
Current Liabilities	41.1%	1,810	1,283	1,405	1,255	1,469	1,411	1,398	1,376	1,600	1,304	1,242	1,113	1,075	646	551	452	310	266	272	239	246
Long Term Debt	-5.1%	1,403	1,478	207	1,417	1,443	1,480	1,241	202	202	201	195	193	184	152	131	82.00	83.00	104	84.00	77.00	41.00
LT Debt, Current	1387.0%	4,886	329	421	282	2,269	3,139	381	2,582	428	442	435	405	2,186	16.00	26.00	11.00	-	1.00	9.00	9.00	9.00
LT Debt, Non Current	-5.1%	1,403	1,478	207	1,417	1,443	1,480	1,241	202	202	201	195	193	184	152	131	82.00	83.00	104	84.00	77.00	41.00
Shareholder's Equity	-6.0%	3,537	3,763	3,799	4,157	4,383	4,655	5,197	5,774	6,133	3,252	3,526	3,927	3,803	4,297	2,546	2,827	940	1,294	1,571	1,623	1,754
Retained Earnings	-4.8%	-7,962	-7,594	-7,809	-7,428	-7,080	-6,635	-5,971	-5,400	-5,076	-4,380	-3,966	-3,486	-3,552	-3,080	-2,654	-2,319	-1,955	-1,567	-1,260	-1,174	-1,007
Additional Paid-In Capital	0.8%	11,599	11,503	11,752	11,645	11,541	11,452	11,357	11,268	11,191	7,725	7,561	7,487	7,415	7,368	5,200	5,138	2,926	2,861	2,814	2,777	2,745
Shares Outstanding	0.5%	1,360	1,353	1,376	1,363	1,356	1,338	1,336	1,332	1,206	1,196	1,194	1,189	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20.00	10.00	15.00	16.00	16.00	17.00	14.00	14.00
Float	-	-	-	10,500	-	-	-	16,800	-	-	-	14,700	-	-	-	7,200	-	-	-	4,900	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-183.6%	-221	-78.15	-293	-563	-318	-561	-379	-236	-507	-495	-420	125	-332	-346	-262	-341	-267	-265	-46.10	-171	-193
Share Based Compensation	-3.2%	93.00	96.00	103	75.00	78.00	78.00	81.00	66.00	63.00	67.00	65.00	46.00	49.00	50.00	45.00	38.00	38.00	37.00	33.00	26.00	26.00
Cashflow From Investing	66.4%	-62.58	-186	68.00	241	39.00	169	659	210	109	-11.99	252	292	-86.92	-1,536	-429	-1,114	-23.89	214	192	172	213
Cashflow From Financing	552.0%	347	-76.78	166	-19.87	-110	120	-17.58	-11.27	3,385	109	36.00	107	326	1,994	81.00	2,802	2.00	25.00	15.00	43.00	9.00
Buy Backs	-100.0%	-	363	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

BGNE Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues
Total revenues	$ 2,458,779	$ 1,415,921	$ 1,176,283
Gross profit	2,078,859	1,129,446	1,011,377
Operating expenses
Research and development	1,778,594	1,640,508	1,459,239
Selling, general and administrative	1,504,501	1,277,852	990,123
Amortization of intangible assets	3,500	751	750
Total operating expenses	3,286,595	2,919,111	2,450,112
Loss from operations	(1,207,736)	(1,789,665)	(1,438,735)
Interest income (expense), net	74,009	52,480	(15,757)
Other income (expense), net	307,891	(223,852)	15,904
Loss before income taxes	(825,836)	(1,961,037)	(1,438,588)
Income tax expense	55,872	42,778	19,228
Net loss	$ (881,708)	$ (2,003,815)	$ (1,457,816)
Net loss per share attributable to BeiGene, Ltd., basic (in dollars per share)	$ (0.65)	$ (1.49)	$ (1.21)
Net loss per share attributable to BeiGene, Ltd., diluted (in dollars per share)	$ (0.65)	$ (1.49)	$ (1.21)
Weighted-average shares outstanding, basic (in shares)	1,357,034,547	1,340,729,572	1,206,210,049
Weighted-average shares outstanding, diluted (in shares)	1,357,034,547	1,340,729,572	1,206,210,049
Net loss per American Depositary Share (ADS), basic (in dollars per share)	$ (8.45)	$ (19.43)	$ (15.71)
Net loss per American Depositary Share (ADS), diluted (in dollars per share)	$ (8.45)	$ (19.43)	$ (15.71)
Weighted-average ADSs outstanding, basic (in shares)	104,387,273	103,133,044	92,785,388
Weighted-average ADSs outstanding, diluted (in shares)	104,387,273	103,133,044	92,785,388
Product
Revenues
Total revenues	$ 2,189,852	$ 1,254,612	$ 633,987
Cost of sales - product	379,920	286,475	164,906
Collaboration revenue
Revenues
Total revenues	$ 268,927	$ 161,309	$ 542,296

BGNE Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS ¥ in Thousands, $ in Thousands	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Current assets:
Cash and cash equivalents	$ 3,171,800	$ 3,869,564
Short-term restricted cash	11,473	196
Short-term investments	2,600	665,251
Accounts receivable, net	358,027	173,168
Inventories, net	416,122	282,346
Prepaid expenses and other current assets	243,392	216,553
Total current assets	4,203,414	5,207,078
Property, plant and equipment, net	1,324,154	845,946
Operating lease right-of-use assets	95,207	109,960
Intangible assets, net	57,138	40,616
Other non-current assets	125,362	175,690
Total non-current assets	1,601,861	1,172,212
Total assets	5,805,275	6,379,290
Current liabilities:
Accounts payable	315,111	294,781
Accrued expenses and other payables	693,731	467,352
Deferred revenue, current portion	0	213,861
Tax payable	22,951	25,189
Operating lease liabilities, current portion	21,950	24,041
Research and development cost share liability, current portion	68,004	114,335
Short-term debt	688,366	328,969
Total current liabilities	1,810,113	1,468,528
Non-current liabilities:
Long-term debt	197,618	209,148
Deferred revenue, non-current portion	300	42,026
Operating lease liabilities, non-current portion	22,251	34,517
Deferred tax liabilities	16,494	15,996
Research and development cost share liability, non-current portion	170,662	179,625
Other long-term liabilities	50,510	46,095
Total non-current liabilities	457,835	527,407
Total liabilities	2,267,948	1,995,935
Commitments and contingencies
Shareholders’ equity:
Ordinary shares, 0.0001 par value per share; 9,500,000,000 shares authorized; 1,359,513,224 and 1,356,140,180 shares issued and outstanding as of December 31, 2023 and 2022, respectively	135	135
Additional paid-in capital	11,598,688	11,540,979
Accumulated other comprehensive loss	(99,446)	(77,417)
Accumulated deficit	(7,962,050)	(7,080,342)
Total shareholders’ equity	3,537,327	4,383,355
Total liabilities and shareholders’ equity	$ 5,805,275	$ 6,379,290

About BeiGene Ltd

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., Enlivex Therapeutics Ltd., Chime Biologics Limited, and Nanjing Leads Biolabs Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

CEO	Mr. John V. Oyler
WEBSITE	beigene.com
INDUSTRY	Biotechnology
EMPLOYEES	10000

BeiGene Ltd Frequently Asked Questions

What is the ticker symbol for BeiGene Ltd? What does BGNE stand for in stocks?

BGNE is the stock ticker symbol of BeiGene Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BeiGene Ltd (BGNE)?

As of Wed Apr 17 2024, market cap of BeiGene Ltd is 179.27 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BGNE stock?

You can check BGNE's fair value in chart for subscribers.

What is the fair value of BGNE stock?

You can check BGNE's fair value in chart for subscribers. The fair value of BeiGene Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BeiGene Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BGNE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BeiGene Ltd a good stock to buy?

The fair value guage provides a quick view whether BGNE is over valued or under valued. Whether BeiGene Ltd is cheap or expensive depends on the assumptions which impact BeiGene Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BGNE.

What is BeiGene Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, BGNE's PE ratio (Price to Earnings) is -203.32 and Price to Sales (PS) ratio is 72.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BGNE PE ratio will change depending on the future growth rate expectations of investors.